ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MIRM / financials
GRFS (54) COGT (42) MANE (55) ERAS (33) ⌘ Pro Terminal →

Mirum Pharmaceuticals Inc. (MIRM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$85.74 +0.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $85.71

Mirum Pharmaceuticals Inc. (MIRM) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $5.52B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MIRM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MIRM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $85.74 (+0.87% 1D, market cap $5.52B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MIRM ranks #250 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MIRM compare to GRFS and COGT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIRM carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -3.9%. By comparison, GRFS (Grifols S.A.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.57B) and COGT (Cogent Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $5.38B). Among the 5-stock peer group, MIRM leads on earnings multiple (N/A) while MIRM leads on capital efficiency (-3.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MIRM?
▼

Per MIRM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759425), Mirum Pharmaceuticals Inc. generated $521.3M in revenue (+54.7% YoY), -$23.4M in net income, and $54.9M in free cash flow against $842.8M in total assets and $237.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $85.71 (-0.03%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 10.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk D+
Cash (13)Whales (7)SEC (16)Macro (6)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.1% Base Target
$137 Bull$83 Base$65 Bear
📬 FREE MIRM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MIRM)Realized 20D OHLCV Swing Band: ±8.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY MIRM SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (31% of score)

Altman Z-Score 6.29 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 10.5% FCF Margin ($54.9M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit6/20 pts (-14 pt drag)

Macro rate sensitivity & RSI-14 (48.4) create a -14 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$79.96+4.4% Next Q
Q2 (-2Q)
46
Grade D$83.44+2.8% Next Q
Q3 (-1Q)
48
Grade D$85.81-0.1% Next Q
Current
51
Grade D$85.74-1.3% Hist 90D α
Trajectory: D (43) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MIRM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MIRM currently carries a cautious 51/100 (D) rating due to Macro Regime Fit (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($89.27) and Max Pain ($90.03) forces dealer call-delta covering toward $136.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.80% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MIRM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MIRM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How MIRM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$54.9M (10.5% FCF Margin)
Revenue$521.3MGross Profit $271.1M (52%)Cost of Sales $250.2MOp Profit $0 (0%)OpEx (R&D/SG&A) $271.1MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $186.4M
FY24
Rev $336.9M
FY25
Rev $521.3M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$521.3M52%-4.2%-$23.4M$54.9M-6.8%
FY 2024$336.9M52%-26%-$87.9M$9.3M-34%
FY 2023$186.4M52%-58.6%-$163.4M-$79.3M-4.6%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MIRM)

  • ✓Walkthrough of MIRM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MIRM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.95%⚡ TESTING RESISTANCE
2026-11-03O $86.39H $86.39L $85.00C $85.74VOL 673.5K
RES: $87.22SUP: $72.23SMA50: $89.27SMA200: $98.48
$133.7$118.5$103.4$88.22$73.08RES $87.22SUP $72.23$85.742026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MIRM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MIRM Butterfly Map → + Track MIRM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
24.7%/yr Implied 5Y Growth

vs. +54.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MIRM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MIRM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MIRM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MIRM)

Health Care Rank #250 of 1015 ⚔️ GRFS vs MIRM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MIRM vs. GRFS, COGT, MANE, ERAS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Mirum Pharmaceuticals Inc. (MIRM) ranks #250 by composite RQD confidence (51/100, grade D) and #150 by equity capitalization ($5.52B). Within this direct 5-issuer industry benchmark cohort, MIRM leads on earnings valuation at N/A trailing P/E, while MIRM leads on capital efficiency and profitability with -3.9% ROIC and — gross margin. MANE currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with MIRM at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MIRM ACTIVE
Mirum Pharmaceuticals Inc.
D 51/100 — — -3.9% +0.87% $5.52B Benchmark Subject
GRFS
Grifols S.A.
D+ 54/100 — — — +5.06% $5.57B /grfs-vs-mirm →
COGT
Cogent Biosciences Inc.
D- 42/100 — — -35.0% -4.16% $5.38B /cogt-vs-mirm →
MANE
Veradermics Incorporated
D+ 55/100 — — -11.9% -7.27% $5.84B /mane-vs-mirm →
ERAS
Erasca Inc.
E 33/100 — — -35.0% -2.09% $5.02B /eras-vs-mirm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001759425 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mirum Pharmaceuticals Inc. (MIRM) reported GAAP revenue of $521.3M (+54.7% vs. FY2024 revenue of $336.9M , and +179.7% cumulative change since FY2023) , GAAP net income of -$23.4M, operating cash flow of $55.8M, and free cash flow of $54.9M (+488.0% YoY). On the balance sheet, MIRM closed FY2025 with $842.8M in total assets against $237.7M in total debt (Altman Z-Score: 6.29, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $521.3M -$23.4M $55.8M $54.9M $842.8M $237.7M
FY2024 (FY) 2024-12-31 $336.9M -$87.9M $10.3M $9.3M $670.8M $200.3M
FY2023 (FY) 2023-12-31 $186.4M -$163.4M -$70.9M -$79.3M $3.09B $721.9M

3. MIRM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MIRM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $85.74 (+0.87% 1D, market cap $5.52B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MIRM ranks #250 in composite RQD confidence.

How does MIRM compare to GRFS and COGT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIRM carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -3.9%. By comparison, GRFS (Grifols S.A.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.57B) and COGT (Cogent Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $5.38B). Among the 5-stock peer group, MIRM leads on earnings multiple (N/A) while MIRM leads on capital efficiency (-3.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MIRM?

Per MIRM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001759425), Mirum Pharmaceuticals Inc. generated $521.3M in revenue (+54.7% YoY), -$23.4M in net income, and $54.9M in free cash flow against $842.8M in total assets and $237.7M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MIRM trading relative to its 50-day, 200-day, and 52-week technical levels?

MIRM last traded at $85.74 (+0.87% on volume of 522,784 shares), positioning the stock -3.95% below its 50-day simple moving average ($89.27) and -12.94% below its 200-day simple moving average ($98.48). Across its 52-week range of $63.23 to $130.00, MIRM sits at the 33.7% percentile with a 14-day RSI of 48.4 (NEUTRAL RANGE) and an implied next-earnings move of ±8.5% ($78.45 to $93.03).

Direct Sub-Reports: MIRM RQD Cockpit MIRM 12M Forecast MIRM Earnings & Move MIRM Dividends & DRIP MIRM Insiders & 13F MIRM Whale Options MIRM Profit Sankey MIRM News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ SEC XBRL & RQD VERIFIED

MIRM — Mirum Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Mirum Pharmaceuticals Inc. (MIRM) earns a live Roarable RQD composite score of 51/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $85.74 (+0.87% 1D, market capitalization $5.52B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of -3.9%, gross margin of —, operating margin of -4.2%, and free cash flow yield of 0.98%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (16/20): Incorporates a 0.99x equity beta, Altman Z-Score of 6.29, Piotroski F-Score of 8/9, and Debt/Equity of 0.70x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Mirum Pharmaceuticals Inc. (MIRM) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. The company reported FY 2025 revenue of $521.3M, indicating an operating business rather than a pre-revenue one. — for further business description.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Mirum Pharmaceuticals Inc. (MIRM) reported $521.3M in annual revenue (up from $336.9M in FY2024, +54.7% YoY) and -$23.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($186.4M revenue, -$163.4M net income) through FY2025, MIRM scaled operating cash flow to $55.8M and free cash flow to $54.9M, backed by $842.8M in total assets against $237.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 51/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 0.98% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $63.23 – $130.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -4.2% operating margins and a 0.99x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MIRM carries a macro regime beta of 0.99 and gross margin of —.

  • Key Question #1: Can MIRM sustain or expand its -4.2% operating margin and -3.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $521.3M and free cash flow of $54.9M, how will capital allocation balance growth reinvestment against $237.7M in total debt?
  • Key Question #3: How sensitive is MIRM's 32.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.99x)?

MIRM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Mirum Pharmaceuticals Inc. (MIRM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MIRM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MIRM Bull vs. Bear Conversation Board — What's Your Call at $85.74?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MIRM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MIRM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $111.35 (+31.0%)
📌 Pinned Debate

Forensic balance sheet scores 16/20 with Altman Z 6.29, Piotroski F 8/9 and debt cut from $721.9M to $237.7M, plus a headline-reported

Don't sleep on MIRM's setup in Health Care. Forensic balance sheet scores 16/20 with Altman Z 6.29, Piotroski F 8/9 and debt cut from $721.9M to $237.7M, plus a headline-reported $151.64 price target.. Beta of 0.99 means it moves fast when momentum turns, and the 5-pillar RQD gauge (51/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

@ForensicBear Shorting a 7/20 institutional whale-flow stock at $85.00 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $71.40 (-16.0%)
Spot @ $85.00

ROIC of -3.9%, FCF yield of 0.98%, and a Whale flow score of 7/20 leave the RQD rating at a 51 D with a distribution-warning label.

Here is the bear case nobody on the bull side wants to address on MIRM: ROIC of -3.9%, FCF yield of 0.98%, and a Whale flow score of 7/20 leave the RQD rating at a 51 D with a distribution-warning label.. At 32.0x forward P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE